Logo for Adaptimmune Therapeutics plc

Adaptimmune Therapeutics Investor Relations Material

Latest events

Logo for Adaptimmune Therapeutics plc

Status Update

Adaptimmune Therapeutics
Logo for Adaptimmune Therapeutics

Status Update

18 Nov, 2024
Logo for Adaptimmune Therapeutics

Q3 2024

13 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Adaptimmune Therapeutics plc

Access all reports
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients, particularly those with solid tumors. The company utilizes a proprietary cell therapy platform to engineer a patient's own cells to target and fight cancer. Adaptimmune is involved in several phase II clinical trials, including SPEARHEAD-1 for synovial sarcoma and SURPASS-3 for platinum-resistant ovarian cancer. Their research and development efforts are supported by strategic collaborations with entities like Genentech, Inc. and F. Hoffman-La Roche Ltd, among others, to further the development and potential commercialization of their therapies. The company is headquartered in Abingdon, United Kingdom, and its shares are listed on the NASDAQ.